Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip

被引:19
|
作者
Tan, Jianfeng [1 ,2 ]
Sun, Xindi [3 ]
Zhang, Jianhua [1 ]
Li, Huili [4 ]
Kuang, Jun [1 ]
Xu, Lulu
Gao, Xinghua [3 ]
Zhou, Chengbin [2 ,4 ]
机构
[1] Southern Med Univ, Dept Thorac Surg, Shenzhen Hosp, Shenzhen 518101, Peoples R China
[2] Southern Med Univ, Sch Clin Med 2, Guangzhou 510030, Peoples R China
[3] Shanghai Univ, Mat Genome Inst, Shanghai 200444, Peoples R China
[4] Guangdong Acad Med Sci, Dept Cardiovasc Surg, Guangdong Prov Cardiovasc Inst, Guangdong Prov Peoples Hosp, Guangzhou 510030, Peoples R China
来源
BIOSENSORS-BASEL | 2022年 / 12卷 / 08期
关键词
lung-on-a-chip; drug evaluation; EGFR; lung cancer; targeted therapy; GEFITINIB; MODELS;
D O I
10.3390/bios12080618
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, we used three-dimensional (3D) printing to prepare a template of a microfluidic chip from which a polydimethylsiloxane (PDMS)lung chip was successfully constructed. The upper and lower channels of the chip are separated by a microporous membrane. The upper channel is seeded with lung cancer cells, and the lower channel is seeded with vascular endothelial cells and continuously perfused with cell culture medium. This lung chip can simulate the microenvironment of lung tissue and realize the coculture of two kinds of cells at different levels. We used a two-dimensional (2D) well plate and a 3D lung chip to evaluate the effects of different EGFR-targeting drugs (gefitinib, afatinib, and osimertinib) on tumor cells. The 3D lung chip was superior to the 2D well plate at evaluating the effect of drugs on the NCI-H650, and the results were more consistent with existing clinical data. For primary tumor cells, 3D lung chips have more advantages because they simulate conditions that are more similar to the physiological cell microenvironment. The evaluation of EGFR-targeted drugs on lung chips is of great significance for personalized diagnosis and treatment and pharmacodynamic evaluation.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Anti-Tumor Effects of Cardiac Glycosides on Human Lung Cancer Cells and Lung Tumorspheres
    Kaushik, Vivek
    Yakisich, Juan Sebastian
    Azad, Neelam
    Kulkarni, Yogesh
    Venkatadri, Rajkumar
    Wright, Clayton
    Rojanasakul, Yon
    Iyer, Anand Krishnan V.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (09) : 2497 - 2507
  • [32] EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity (vol 157, pg 287, 2012)
    Sandoval, Michael A.
    Sloat, Brian R.
    Lansakara-P, Dharmika S. P.
    Kumar, Amit
    Rodriguez, B. Leticia
    Kiguchi, Kaoru
    Digiovanni, John
    Cui, Zhengrong
    JOURNAL OF CONTROLLED RELEASE, 2025, 378 : 1154 - 1154
  • [33] Fuzi Enhances Anti-Tumor Efficacy of Radiotherapy on Lung Cancer
    Zhang, Qi
    Chen, Xue
    Luo, Youjun
    Ren, Huaping
    Qiao, Tiankui
    JOURNAL OF CANCER, 2017, 8 (19): : 3945 - 3951
  • [34] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Nebhan, Caroline A.
    Pirazzoli, Valentina
    Wang, Lu
    Lu, Pengcheng
    Vuong, Huy
    Hutchinson, Katherine E.
    Jia, Peilin
    Chen, Xi
    Eisenberg, Rosana
    Ladanyi, Marc
    Politi, Katerina
    Zhao, Zhongming
    Lovly, Christine M.
    Cross, Darren A. E.
    Pao, William
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
  • [35] Current perspectives on the use of miRNA as a biomarker for EGFR-targeted therapy for non-small cell lung cancer
    Florczuk, Mateusz
    Szpechcinski, Adam
    Chorostowska-Wynimko, Joanna
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2017, 71 : 1207 - 1218
  • [36] Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
    Umelo, Ijeoma Adaku
    De Wever, Olivier
    Kronenberger, Peter
    Van Deun, Jan
    Noor, Alfiah
    Singh, Kshitiz
    Teugels, Erik
    Chen, Gang
    Bracke, Marc
    De Greve, Jacques
    ONCOTARGET, 2015, 6 (24) : 20132 - 20144
  • [37] Reduced Risk of Incident Chronic Obstructive Pulmonary Disease Following EGFR-targeted Therapies in Patients With Lung Cancer
    Chan, S.
    Huang, P.
    Ma, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [38] Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
    Zhang, Shuo
    Chen, Zhen
    Shi, Puyu
    Fan, Songqing
    He, Yong
    Wang, Qiming
    Li, Yixiang
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Sun, Shi-Yong
    THERANOSTICS, 2021, 11 (08): : 3964 - 3980
  • [39] Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer
    Porciuncula, Angelo
    Appleman, Vicky A.
    Parent, Alex
    Raizer, Jeff
    Gregory, Richard C.
    Lineberry, Neil
    Abu-Yousif, Adnan O.
    Schalper, Kurt A.
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Cytokine Profile in Lung Cancer Patients: Anti-Tumor and Oncogenic Cytokines
    Essogmo, Freddy Elad
    Zhilenkova, Angelina V.
    Tchawe, Yvan Sinclair Ngaha
    Owoicho, Abah Moses
    Rusanov, Alexander S.
    Boroda, Alexander
    Pirogova, Yuliya N.
    Sangadzhieva, Zaiana D.
    Sanikovich, Varvara D.
    Bagmet, Nikolay N.
    Sekacheva, Marina I.
    CANCERS, 2023, 15 (22)